+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS). Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

May 09, 2023: Bulletin from Swedish Orphan Biovitrum (Sobi's Annual General Meeting (AGM
Apr 27, 2023: Sobi publishes Q1 2023 report
Apr 19, 2023: Invitation of Sobi's Q1 2023 report
Apr 03, 2023: Sobi publishes Annual and sustainability report for 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Swedish Orphan Biovitrum AB - Key Facts
  • Swedish Orphan Biovitrum AB - Key Employees
  • Swedish Orphan Biovitrum AB - Key Employee Biographies
  • Swedish Orphan Biovitrum AB - Major Products and Services
  • Swedish Orphan Biovitrum AB - History
  • Swedish Orphan Biovitrum AB - Company Statement
  • Swedish Orphan Biovitrum AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Swedish Orphan Biovitrum AB - Business Description
  • Product Category: Hematology
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Specialty Care
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: North America
  • Performance
  • Geographical Segment: Other
  • Performance
  • Overview
  • Geographical Segment: Rest of the World
  • Performance
  • Swedish Orphan Biovitrum AB - Corporate Strategy
  • Swedish Orphan Biovitrum AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Swedish Orphan Biovitrum AB - Strengths
  • Swedish Orphan Biovitrum AB - Weaknesses
  • Swedish Orphan Biovitrum AB - Opportunities
  • Swedish Orphan Biovitrum AB - Threats
  • Swedish Orphan Biovitrum AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Swedish Orphan Biovitrum AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2023: Bulletin from Swedish Orphan Biovitrum (Sobi's Annual General Meeting (AGM
  • Apr 27, 2023: Sobi publishes Q1 2023 report
  • Apr 19, 2023: Invitation of Sobi's Q1 2023 report
  • Apr 03, 2023: Sobi publishes Annual and sustainability report for 2022
  • Mar 30, 2023: Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
  • Feb 08, 2023: Sobi publishes Q4 and FY 2022 report
  • Feb 02, 2023: Swedish Orphan Biovitrum Announces Changes to management
  • Jan 27, 2023: Sobi's Invitation for Q4 and FY 2022 report
  • Nov 18, 2022: Bo Jesper Hansen proposed as new Chairman of the Board of Swedish Orphan Biovitrum AB (publ) ahead of the Annual General Meeting in 2023
  • Nov 11, 2022: Sobi to present new data at the ASH 2022 Annual Meeting
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Swedish Orphan Biovitrum AB, Key Facts
  • Swedish Orphan Biovitrum AB, Key Employees
  • Swedish Orphan Biovitrum AB, Key Employee Biographies
  • Swedish Orphan Biovitrum AB, Major Products and Services
  • Swedish Orphan Biovitrum AB, History
  • Swedish Orphan Biovitrum AB, Subsidiaries
  • Swedish Orphan Biovitrum AB, Key Competitors
  • Swedish Orphan Biovitrum AB, Ratios based on current share price
  • Swedish Orphan Biovitrum AB, Annual Ratios
  • Swedish Orphan Biovitrum AB, Interim Ratios
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Swedish Orphan Biovitrum AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Swedish Orphan Biovitrum AB, Performance Chart (2018 - 2022)
  • Swedish Orphan Biovitrum AB, Ratio Charts
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Vivesto AB
  • BioGaia AB
  • Hansa Biopharma AB
  • AMAG Pharmaceuticals Inc
  • Slottsviken Fastighetsaktiebolag
  • New Nordic Healthbrands AB
  • Hansa Biopharma AB
  • AMAG Pharmaceuticals Inc
  • Fastilium Property Group AB
  • Vivesto AB
  • BioGaia AB
  • New Nordic Healthbrands AB
  • Fastilium Property Group AB
  • Slottsviken Fastighetsaktiebolag